Treatment with doxorubicin plus trabectedin (Yondelis), followed by trabectedin maintenance, improved overall survival (OS) and progression-free survival (PFS) in patients with metastatic or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results